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genic cytokine) in liver biopsy specimens from 28 patients with chronic hepatitis C and five controls, using a quantitative reverse transcription polymerase chain reaction (RT-PCR) assay. Results of mRNA quantification were correlated with histological lesions scored semiquantitatively in the same specimens. Results-Type I collagen mRNA was more strongly expressed in patients than in controls and correlated with the degree of fibrosis, but not with any of the necroinflammatory lesions (portal inflammation, piecemeal necrosis, and lobular necrosis). TGF1l mRNA concentration was higher in patients than in controls and correlated with histological grade ofactivity and lobular necrosis. This result was confirmed by in situ hybridisation experiments which showed that TGFf1 mRNA was mainly expressed in areas of focal lobular necrosis in chronic hepatitis C. Conclusion-This study shows that fibrosis, rather than necro-inflammatory lesions or activity scores, is associated with fibrogenesis and thus with potential aggravation of the fibrous deposit in chronic hepatitis C. Lobular necrosis is an important predictor of prognosis in chronic hepatitis C, as shown by its strong association with TGFP1 mRNA expression. The course of chronic hepatitis C virus (HCV) infection, even after antiviral treatment, is difficult to predict. Although the disease is frequently asymptomatic, the development of liver fibrosis is common, and cirrhosis, occurring in about one in five cases, is the major complication of this chronic disease.' There are no reliable biological or clinical indicators that can predict which patients will develop fibrosis, but if found, these would also help select appropriate patients for antiviral treatment.
Liver biopsy is used to assess the extent of liver damage, as a means of monitoring disease progression, and as a source of information for correct management. Histological examination of the liver biopsy specimens allows activity and fibrosis to be assessed.2 3 Activity gives an overall picture of the degree of necro-inflammatory lesions (grade), while fibrosis reflects the disruption to the liver architecture (stage).2 It has been suggested that in hepatitis B virus infection fibrosis is the result of activity, and thus histological activity might predict the subsequent development of fibrosis or cirrhosis. 4 This hypothesis has been extended to chronic hepatitis C so that the presence of histological activity is a major criterion for starting antiviral treatment. However, this has been challenged, as data from several series of liver biopsy specimens from patients with chronic hepatitis C showed that activity is usually mild, but that fibrosis and cirrhosis are common findings.'68
As far as we are aware no studies have assessed the predictive value of these different histological features in terms of the aggravation of liver fibrosis in chronic hepatitis C.
Liver tissue can also be used to investigate tissue markers of ongoing fibrogenesis, a complex process that examines the different extracellular matrix (ECM) components, such as collagens, fibronectin, and proteoglycans.' 10 In liver fibrosis and cirrhosis, collagens, especially type I collagen, are much in evidence." Furthermore, type I collagen mRNA seems to be a definitive and reliable marker for fibrogenic activity and so of potential fibrous deposition.'2 13 The aim of this study was to determine the pathological features associated with the potential progression to fibrosis in chronic hepatitis C. We therefore evaluated the degree of fibrogenesis in liver biopsy specimens by quantification of liver type I collagen mRNA, using a sensitive quantitative reverse transcriptionpolymerase chain reaction (RT-PCR) assay. We also performed semiquantitative scoring of the different pathological features present in the same liver biopsy specimens and assessed the correlations between histological scores and type I collagen mRNA concentration.
As transforming growth factor (TGF) f31 has a major role in the pathogenesis of fibrosis in chronic hepatitis and cirrhosis-mainly by stimulation of fat storing cells, the main cellular source of matrix proteins'415 we also quantified its mRNA concentration in the same biopsy specimens and correlated it with histological variables. TGFP1 mRNA expres-sion was also studied using in situ hybridisation and the results compared with quantitative data. Twenty eight patients (nine women and 19  men; mean age 48 years, range 29-69 years) were included in the study. All patients were positive for antibody to HCV by second generation tests. Serum viral load was quantified by branched DNA (Amplec Chiron, Chriron, Emeryville, California, USA). Genotypes were also determined by a competitive oligonucelotide priming (COP) PCR assay in 21 patients. 16 Serum aminotransferases (ALT), bilirubin, and y-glutamyltranspeptidase were measured on entry to the study. None of the patients had received antiviral treatment. The delay between presumed infection and time of inclusion was determined for 19 patients. Selection of patients was based on consecutive recruitment and on the availability of enough liver tissue to perform both an accurate histological study and RNA extraction for mRNA quantification.
Methods
Twelve patients received interferon a 2b (Intron-A, Schering Plough, UK) in a dose of 3 mU, three times weekly for six months. Two patients were non-responders (no improvement in ALT activity during treatment), four were partial responders (decrease of less than 50% of initial value of ALT), and six were complete responders (return to normal of ALT values).
Five patients without HCV infection, normal liver function tests, and neither chronic hepatitis nor fibrosis on the biopsy specimen, constituted the control group.
Liver biopsy specimens were obtained for each patient using a percutaneous procedure. About half of each specimen was immediately frozen in liquid nitrogen and stored at -80°C until RNA extraction was performed; the rest of the specimen was fixed, embedded in paraffin wax and processed for histological study according to standard procedures.
A set of representative paraffin wax embedded liver biopsy specimens showing chronic HCV infection with differing degrees of activity were selected for in situ hybridisation. These were cut into 5 jm thick sections.
HISTOLOGICAL ANALYSIS OF LIVER BIOPSY SPECIMENS
Liver biopsy specimens were examined simultaneously by two different pathologists, neither of whom was aware of clinical and biological data except for positivity for antibody to HCV.
For each liver biopsy specimen, the semiquantitative assessment of elementary features potentially present in HCV hepatitis was performed using a standardised questionnaire.'7 The following lesions were recorded: portal fibrosis (FO = no fibrosis, Fl = portal fibrosis without septa, F2 = portal fibrosis with rare septa, F3 = numerous septa without cirrhosis, F4 = cirrhosis); focal lobular necrosis (0 = less than one necro-inflammatory focus per lobule, 1 = at least one necro-inflammatory focus per lobule, 2 = several necro-inflammatory foci per lobule or confluent or bridging necrosis); portal inflammation (0 = absent, 1 = presence of mononuclear aggregates in some portal tracts, 2 = mononuclear aggregates in all portal tracts, 3 = large and dense mononuclear aggregates in all portal tracts); and piecemeal necrosis (0 = absent, 1 = focal alteration of periportal plate in some portal tracts, 2 = diffuse alteration of periportal plate in some portal tracts or focal lesions around all portal tracts, 3 = diffuse alteration of periportal plate in all portal tracts). Fatty changes (micro and/or macrovesicular) were graded as 0 = absent, 1 = mild, 2 = moderate, 3 = severe. Bile duct damage was also reported.
The activity of chronic hepatitis was recorded as follows: AO = no histological activity, Al = minimal activity, A2 = moderate activity, A3 = severe activity. The degree of disease activity was defined by the integrated assessment of all necro-inflammatory lesions according to an algorithm, including piecemeal necrosis as a major decision criterion and lobular necrosis as a secondary criterion. The reproducibility of this activity grading was reported as acceptable according to a previous study.'7 Finally, the histological activity index of Knodell et al'8 (periportal ± bridging necrosis, lobular necrosis, inflammation and portal fibrosis scores) was separately recorded.
Total RNA was isolated from frozen liver tissue using a method derived from the procedure of Chomczynski and Sacchi.'9 The concentration and purity of total RNA were evaluated by spectrophotometry at 260 and 280 nm. The quality of RNA was also controlled by electrophoresis on a 1 % agarose gel by checking the 18S and 28S RNA bands.
Type I collagen and TGFp1 mRNA of each liver biopsy specimen were quantified by a quantitative RT-PCR assay.20 Expression of an endogenously expressed RNA (transcription factor TFIID) was used as the internal control for each specimen. Each sample was normalised on the basis of its internal control content (TFIID).
Reverse transcription of total RNA was per- A cocktail of single stranded oligonucleotides, chemically synthesised, and modified at the 5' end with digoxigenin by the manufacturer (R and D Systems Inc., Minnesota, USA) was used. It consisted of an equimolar mixture of three exon specific probes based on the antisense sequence of exon 6 (28 mer), exon 7A (27 mer), and exon 7B (26 mer) of the TGFl1 gene.
In situ hybridisation was performed on paraffin wax embedded liver sections, as described before.2' Briefly, sections were dewaxed in xylene and graded ethanol, rinsed in DEPC water for five minutes, and treated with proteinase K at a final concentration of 10 ,ug/ml for 10 minutes at 37°C in 50 mM TRIS, pH 7.6. Slides were post-fixed in 0.4% paraformaldehyde in lx PBS for 20 minutes at 4°C. Liver sections were then hybridised overnight at 370C in 4x SSC, 50% formamide, lx Denhart's solution, 5% dextran sulphate, 0.5 mg/ml salmon sperm DNA, 0.25 mg/ml yeast tRNA containing 500 ng/ml of digoxigenin labelled TGFP1 antisense probe. After washing in decreasing concentrations of SSC (sodium citrate/sodium chloride) (twice for five minutes in 4x SSC at 37°C, twice for five minutes in 2x SSC at 37°C, and once in lx SSC for 15 minutes at room temperature), tissue sections were incubated with anti-digoxigenin antibody at a 1 in 500 dilution (Boehringer Mannheim, Mannheim, Germany) in 100 mM TRIS-HCI, 150 mM NaCl, pH 7.5, for 20 minutes at 37°C. After two rinses in the same buffer for five minutes and washing in DEPC-water with levamisole 1 mM, alkaline phosphatase was detected using 5-bromo-4-chloro-3-indolyl phosphate and nitro blue tetrazolium chloride.
Digoxigenin labelled sense oligonucleotide as well as sections incubated without probe were used as negative controls. Liver sections incubated with a digoxigenin labelled poly-dT oligoprobe and recombinant CHO cell lines expressing TGF31 incubated with the TGFP1 antisense probe were used as positive controls. These controls were systematically processed in each experiment and under the same conditions.
Results
The mean delay between presumed infection and liver biopsy was 16.8 months (range seven to 40 months) in the 19 patients for whom data were available. The mean (SD) values of serum ALT, bilirubin, and y-glutamyltranspeptidase were, respectively: 2.9N (2.1), 9.4 (3.61) ,umol/l and 5N (0.8) ( mild activity (Al), 14 had moderate activity (A2), and one had severe activity (A3). The mean value of the Knodell index was 8.3 (2.2) (range [5] [6] [7] [8] [9] [10] [11] [12] . ' Type I collagen and TGFf1 mRNA were quantified in the livers of 28 patients with chronic hepatitis C and in five controls. The concentrations of type I collagen and TGFI1 mRNA in each subject were normalised to that of the TFIID mRNA value in the same biopsy sample. The mean coefficients of variation of triplicate assessments of TFIID, type I collagen, and TGF3l mRNA in the 30 samples were, respectively: 0.06 (range 0.02-0.10), 0.1 1 (0.04-0.15), and 0.06 (range 0.01-0.09).
In the control group the mean concentration of type I collagen mRNA was 0.43 (0.08) and that of TGF 1 mRNA was 0.15 (0.08). In patients with chronic hepatitis C type I collagen mRNA was 1.7 (1.9), which was significantly higher than that in the control group (p < 0.01). The mean TGFP1 mRNA in patients with chronic hepatitis C was 0.5 (0.3), significantly higher than that of the control group (p < 0.01). Among patients with significant fibrosis (F>F2), mean type I collagen mRNA was not significantly different between patients with no or mild activity (AO or Al, n = 8, 1.4 (1.2)) and those with moderate or severe activity (A2 or A3, n = 10, 2.3 (2.5)).
To analyse in more detail the correlation between type I collagen mRNA and histological features, the patients were divided into two groups according to the concentration of type I collagen mRNA: those with higher than the median value (>1.1, n = 15) and those with lower than the median value (<1.1, n = 13).
Comparisons between these two groups showed that the degree of fibrosis was significantly higher in the group of patients with higher type I collagen mRNA than in the other group (2.3 (1.0) vs 1.5 (0.7) ; p = 0.01). No significant difference was observed for other histological features. 
The patients were divided into two groups according to the concentration of TGF,1 mRNA: those with above the median value (>0.4, n = 16) and those with below (<0.4, n = 12). Comparisons between these two groups showed that the degree of lobular necrosis and histological activity according to METAVIR was significantly higher in the group of patients with TGF[1 mRNA than the other group (lobular necrosis: 0.9 (0.4) vs 0.4 (0.4), p = 0.03; activity 1.7 (0.6) vs 1.1 (0.8), p = 0.04). A significant trend was also observed for fibrosis (1.5 (0.9) vs 2.2 (1.0), p = 0.06). No significant differences were observed for other histological features.
The mean concentration of type I collagen mRNA in the non-or partial responders was higher but not significantly different (1.95 (2.45)) from that in the complete responders (0.66 (0.66)). TGF,1 mRNA was also higher, but not significantly different (0.56 (0.3)), in the non-or partial responders from that in complete responders (0.39 (0.28)).
In liver biopsy specimens of chronic hepatitis C TGFI31 mRNA was expressed in isolated mononuclear cells of portal tracts and periportal inflammatory infiltrate as well as in some cells of the hepatic capsule (fig 1) . In chronic hepatitis with severe activity, the major source of TGFP1 mRNA was detected in the liver lobule (fig 2A) . An intense signal was observed in focal areas of lobular necrosis composed of aggregates of mononuclear inflammatory cells in contact with a few necrotic liver cells. Close to these areas, TGFP 1 transcripts were also detected in perisinusoidal cells (fig 3) control to monitor the extent of degradation and recovery of mRNA, and to control sample to sample variations. For this reason, we quantified TFIID in each biopsy sample, a consistently expressed transcriptional factor. For each sample, results of mRNA quantification (type I collagen and TGF 1) were expressed on the basis of its internal control (TFIID) content.
Type I collagen mRNA expression was increased in patients with chronic hepatitis C. A wide range of mRNA values was observed in this group and it may be related to the sampling ofpatients, based only on an anti-HCV positive serology irrespective of an increase in transaminase activity or histological lesion.
To assess the histological lesions reflecting ongoing fibrogenesis, we correlated type I collagen mRNA with semiquantitative scores of the different histological lesions. Interobserver variation is a major drawback in the semiquantitative assessment of histological features in hepatitis C."7 To minimise interobserver variations, two pathologists experienced in liver pathology performed simultaneous readings of all biopsy specimens, as we had already shown that this procedure significantly decreased interobserver variations.'7 Analysis of results showed that the degree of fibrosis was the only histological lesion that correlated with the type I collagen mRNA concentration. This result means that, in chronic hepatitis C, a preexisting fibrosis is a predictive histological indicator of further aggravation of fibrosis.
None of the necro-inflammatory lesions, whether taken independently or combined in a scoring system, correlated with an increase in type I collagen mRNA, either throughout the whole group of patients or in the group of patients with clinically important fibrosis. Our data suggest that fibrosis is at least as important as grade in the prediction of further fibrosis. These results also underline the usefulness of independent assessment of activity (grade) and fibrosis (stage), as recently recommended.2 3 If these results are confirmed in a larger group the presence of fibrosis, whatever the degree of histological activity, would have to be considered when selecting patients for treatment.
Our study shows that TGF 1 mRNA is highly correlated with histological grade according either to METAVIR'7 or the Knodell index.'8 Furthermore, among the different primary necro-inflammatory features, only lobular necrosis correlates with the increase in TGF 1 mRNA value. This finding emphasises the importance of this histological feature in the global assessment of necro-inflammatory features (activity) and in the fibrogenetic process in hepatitis C. Results of our in situ hybridisation experiments confirm these data.
Like other similar studies" 2 2 we detected TGF,1 mRNA in some portal and periportal inflammatory cells in chronic hepatitis C. Furthermore, when activity was pronounced, we found that a major site of TGFP1 mRNA production were areas of focal lobular necrosis and that perisinusoidal cells adjacent to these areas of lobular necrosis also strongly expressed TGFP1 mRNA. Taken together, these results fit well with the concept that, in chronic hepatitis C, aggravation of chronic histological lesions occurs throughout episodes of lobular necrosis.2
Discrepancies exist concerning a correlation between TGF1 mRNA concentration and piecemeal necrosis or portal inflammation. While Castilla et al'2 found a significant correlation between the TGF,B1 mRNA concentration and all necro-inflammatory lesions included in the Knodell index, Roulot et alf9 found none. These differences could be explained by patient sampling as some studies included patients with both chronic hepatitis B and C,22 or else by the different mRNA quantification procedures used. Another major factor is the accuracy of the histological analysis, as we have already shown high interobserver variations in the assessment of histological lesions in chronic hepatitis C, especially necroinflammatory features such as piecemeal necrosis and portal inflammation."
Several studies have emphasised the importance of the HCV genotype and viral load in the severity of disease and the treatment response. 30 We found no correlations between either type I collagen or TGF31 mRNA with the HCV genotype or viral load. Furthermore, although higher type I collagen and TGF,1 mRNA concentrations were observed in the non-or partial responders than in the complete responders, differences did not reach significance.
We have shown that the expression of type I collagen mRNA in the liver correlates with TGFp1 mRNA. This agrees with previous studies using semiquantitative mRNA procedures. 22 23 Furthermore, in our study, we found a trend for correlation between an increase in the TGF 1 mRNA concentration and semiquantitative scoring of fibrosis. These results suggest that TGFP1 has a role in the fibrogenesis in hepatitis C.
In conclusion, our study shows that the histological features of necro-inflammation and fibrosis differ in their correlation with a sensitive marker of fibrogenesis in chronic hepatitis C. This underlines the importance of separate assessment of these two features in chronic hepatitis C liver biopsy reports. The correlation between lobular necrosis and TGF,B1 mRNA suggests a major role for this lesion in chronic hepatitis C.
